MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas

Human Pathology. Volume 36, Issue 11, Pages 1163-1167 (November 2005). Received 26 July 2005; received in revised form 15 August 2005; accepted 17 August 2005 published online 26 September 2005. [Link]

Nelson G. Ord�ñez

Department of Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA

Abstract

The differential diagnosis between peritoneal mesotheliomas and serous carcinomas involving the peritoneum may be difficult, but it can be facilitated by the use of immunohistochemistry. To determine whether estrogen receptors (ER) or progesterone receptors (PR) may have any value as immunohistochemical markers for discriminating between these malignancies, 40 serous carcinomas of the ovary metastatic to the peritoneum, 7 primary peritoneal serous carcinomas, 30 epithelioid peritoneal malignant mesotheliomas, 5 well-differentiated papillary mesotheliomas, and 4 adenomatoid tumors were immunostained for ER and PR. Reactivity for ER was obtained in 35 (88%) of the metastatic serous carcinomas of the ovary and 6 (86%) of the primary peritoneal serous carcinomas, whereas positivity for PR was observed in 24 (60%) of the metastatic serous carcinomas and 4 (56%) of the primary peritoneal serous carcinomas. None of the mesotheliomas or adenomatoid tumors expressed ER or PR. It is concluded that, because of its high sensitivity for serous carcinomas, ER immunostaining could be very useful in distinguishing between serous carcinomas and peritoneal mesotheliomas. Immunostaining for PR, however, has little practical utility.

Keywords: Mesothelioma, Serous carcinoma, Estrogen receptors, Progesterone receptors, Immunohistochemistry

Both comments and trackbacks are currently closed.